Luye Innomind Pharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for LUYE INNOMIND PHARMA, and when can generic versions of LUYE INNOMIND PHARMA drugs launch?
LUYE INNOMIND PHARMA has one approved drug.
There are two US patents protecting LUYE INNOMIND PHARMA drugs.
There are seven patent family members on LUYE INNOMIND PHARMA drugs in six countries and five supplementary protection certificates in three countries.
Summary for Luye Innomind Pharma
| International Patents: | 7 |
| US Patents: | 2 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Luye Innomind Pharma
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-006 | Jul 26, 2024 | RX | Yes | Yes | 12,128,049 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-003 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-001 | Jul 26, 2024 | RX | Yes | Yes | 12,128,049 | ⤷ Sign Up | ⤷ Sign Up | ||||
| Luye Innomind Pharma | ERZOFRI | paliperidone palmitate | SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR | 216352-004 | Jul 26, 2024 | RX | Yes | Yes | 11,666,573 | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Luye Innomind Pharma Drugs
Supplementary Protection Certificates for Luye Innomind Pharma Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0368388 | SPC/GB07/065 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT; REGISTERED: UK EU/1/07/395/001 20070625; UK EU/1/07/395/002 20070625; UK EU/1/07/395/003 20070625; UK EU/1/07/395/004 20070625; UK EU/1/07/395/005 20070625; UK EU/1/07/395/006 20070625; UK EU/1/07/395/007 20070625; UK EU/1/07/395/008 20070625; UK EU/1/07/395/009 20070625; UK EU/1/07/395/010 20070625; UK EU/1/07/395/011 20070625; UK EU/1/07/395/012 20070625; UK EU/1/07/395/013 20070625; UK EU/1/07/395/014 20070625; UK EU/1/07/395/015 20070625; UK EU/1/07/395/016 20070625; UK EU/1/07/395/017 20070625; UK EU/1/07/395/018 20070625; UK EU/1/07/395/019 20070625; UK EU/1/07/395/020 20070625; UK EU/1/07/395/021 |
| 0904081 | 11C0035 | France | ⤷ Sign Up | PRODUCT NAME: PALMITATE DE PALIPERIDONE; REGISTRATION NO/DATE: EU/1/11/672/001 20110304 |
| 0368388 | 07C0044 | France | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONE; REGISTRATION NO/DATE IN FRANCE: EU/1/07/395/01 DU 20070626; REGISTRATION NO/DATE AT EEC: EU/1/07/395/01 DU 20070625 |
| 0904081 | SPC/GB11/044 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: PALIPERIDONE PALMITATE; REGISTERED: UK EU/1/11/672/001 20110304; UK EU/1/11/672/002 20110304; UK EU/1/11/672/003 20110304; UK EU/1/11/672/004 20110304; UK EU/1/11/672/005 20110304; UK EU/1/11/672/006 20110304 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
